Navigation Links
Viral protein is an effective preventative against infection

For parents, 8 million cases of acute middle ear infections every year add up to a lot of sleepless nights and trips to the pediatrician. But new research from a collaboration between Rockefeller University and St. Jude Children’s Hospital could change all that.

In the March 23 issue of PLoS Pathogens, Rockefeller’s Vincent A. Fischetti and colleagues at St. Jude show that middle ear infections in mice can be prevented by giving the mice a lysin ?a protein derived from a virus that infects bacteria. The new technology may prevent children with the flu from developing secondary ear infections and would be an attractive alternative to traditional antibiotics, to which bacteria are rapidly becoming resistant.

The bacteria that cause middle ear infections, Streptococcus pneumoniae, aren’t transmitted at school. They already reside on the mucosal membranes in the nose, waiting for their chance to strike. When a child catches the flu, or another virus that causes an upper respiratory infection, the bacteria seize the opportunity and migrate to the middle ear, causing a secondary infection. The new treatment would kill the bacteria before it had a chance to move.

"These bacteria take advantage of a viral infection by striking when our resistance is lowered," says Fischetti, head of Rockefeller’s Laboratory of Bacterial Pathogenesis and Immunology. "You should start taking an antibiotic the moment you come down with the viral infection to prevent the secondary infection, but physicians are reluctant to do this for fear of increasing resistance to antibiotics. So we’re really in a catch-22 situation."

Fischetti’s lab has done extensive research on lysins, which are proteins derived from viruses that normally infect bacteria. After a virus has infected the bacteria and replicated, it uses lysins to punch holes in the bacteria’s cell wall, killing the bacteria, in order to escape. Fischetti’s lab has studied many different lysins and found that they work even from outside the bacterial cell as well as from the inside. In addition, unlike antibiotics, which kill many of the body’s beneficial bacteria along with the disease-causing ones they target, lysins are highly specific. Each lysin will only kill a specific type of bacteria, leaving the body’s normal flora untouched.

"We knew from our previous experiments that if you treat an animal infected or colonized with pneumococci or streptococci with these lysins, you could cure or decolonize them," says Fischetti. "But I was looking for a way to see if lysins would work for secondary infections too, and John McCullers had a very nice model system."

The two researchers collaborated ?Fischetti sent McCullers, a physician at St. Jude Children’s Hospital Department of Infectious Diseases, the lysin, and McCullers tested his mice. He colonized his mice with S. pneumoniae, treated some of them with the lysin and then gave them all influenza. Eighty percent of the mice that did not receive the lysin came down with middle ear infections, but none of the mice given the lysin did. The treatment was 100 percent effective.

"It is really a no-brainer experiment," says Fischetti. "If the bacteria aren’t there, they cannot cause the secondary infection."

"Secondary bacterial infections cause much of the sickness and about 25 percent of all deaths during flu season," says McCullers. "Eliminating these secondary infections could dramatically reduce sickness and death rates."
'"/>

Source:Rockefeller University


Related biology news :

1. Viral DNA sequence a possible trigger for breast cancer
2. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
3. Viral protein influences key cell-signaling pathway
4. Viral protein helps infected T cells stick to uninfected cells
5. Viral fitness explains different resistance patterns to aids drugs
6. Viral genetic differences are possible key to HIV dementia
7. Viral hitchhiker inhibits Wolbachia bacterias ability to proliferate
8. Viral marker of human migration suspect
9. New, automated tool successfully classifies and relates proteins in unprecedented way
10. New binding target for oncogenic viral protein
11. Controversial drug shown to act on brain protein to cut alcohol use

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:5/24/2016)... May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology ... LCD display is the latest premium product recently added to the range of products ... ... ... 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of ... their brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been ... Target to its list of well-respected retailers. This list includes such fine stores ...
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: